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The registered incidence rate of childhood central nervous system (CNS) tumours has increased in several countries. It is uncertain
whether these increases are biologically real or owing to improved diagnostic methods. We explored the medical records of 626
CNS tumours diagnosed in Danish children between 1980 and 1996. Population-based registers were used to extract data on
mortality and background population. Temporal patterns were analysed by regression techniques. Most tumours were verified by
computed tomography (78%) or magnetic resonance imaging (14%). Overall, the incidence rate increased by 2.9% per year (95%
confidence interval (CI): 1.3;4.5) and the mortality rate increased by 1.4% per year (95% CI:  0.4;3.3). Among children aged 0–4
years, the survival rate after diagnosis remained almost unchanged, whereas among children aged 5–14 years, the 10-year survival
rate improved from 59 to 74%. These data suggest that the incidence rate of CNS tumours among Danish children has truly
increased, although alternative explanations cannot be excluded.
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Increasing incidence rates of central nervous system (CNS)
tumours in children have been reported for several populations
in countries where incident cancer cases are registered routinely,
that is, in Australia, Italy, Sweden, the United Kingdom and the
USA (Mosso et al, 1992; McKinney et al, 1994; Giles et al, 1995;
Bunin et al, 1996; Gurney et al, 1996; Hjalmars et al, 1999; McNally
et al, 2001; Dreifaldt et al, 2004). It is uncertain whether these
increases are owing to improved diagnostic methods, changes in
cancer registration procedures or changes in tumour classification
practices, or whether the increases are biologically real and owing
to changes in environmental or lifestyle factors (Black, 1998; Smith
et al, 1998; Forman, 1999; Schechter, 1999; Varner, 1999).
In Sweden, the increase occurred throughout the 20-year period
1973–1992 (Hjalmars et al, 1999), covering the introduction of
both computed tomography (CT) and magnetic resonance imaging
(MRI) as diagnostic methods. In contrast, the increase in the
incidence rate of childhood CNS tumours in the United Kingdom
occurred mostly before the introduction of MRI (McKinney et al,
1994; McNally et al, 2001). In the USA, the increase in childhood
CNS tumour incidence rate occurred within a few years during the
mid-1980s, when MRI became widespread (Steinberg, 1986; Smith
et al, 1998), and was preceded and followed by relatively stable
rates (Gurney et al, 1996; Smith et al, 1998); at the same time, a
slight but steady decrease in specific mortality from CNS tumours
in childhood was registered (Linet et al, 1999).
So far, the use of MRI for the diagnosis of CNS tumours has
been quantified by the number of scanners available (Smith et al,
1998) or, in the USA, by the rate of MRI use by Medicare
participants (Legler et al, 1999). The temporal patterns thus
obtained do not, however, necessarily reflect the actual use of MRI
in the diagnosis of childhood CNS tumours. In the present study,
we explored the temporal patterns of childhood CNS tumour
incidence rates in relation to actual use of CT and MRI for
diagnosis of the single patient.
MATERIALS AND METHODS
Tumour identification
We studied primary CNS tumours (including also nonmalignant
types) diagnosed in Denmark during childhood (0–14 years)
between 1 January 1980 and 31 December 1996. The year 1980 was
chosen to begin the study period before introduction of MRI in
Denmark and 1996 was the most recent year with complete
data available in the Danish Cancer Registry, when the study
was initiated. The tumours had to conform to diagnostic group
III of the classification scheme suggested Birch and Marsden
(1987), which consists of astrocytoma, medulloblastoma, ependy-
moma, ‘other glioma’, and ‘miscellaneous intracranial and
intraspinal neoplasms’. Central nervous system tumours outside
group III of the classification scheme, for example, intracranial
germ-cell tumours, were not included. As suggested by the
International Agency for Research of Cancer in 1996, the group
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yof medulloblastomas was expanded to include ‘other primitive
neuroectodermal tumours’ (Kramarova and Stiller, 1996). Tumours
that potentially complied with our inclusion criteria were
identified in the population-based Danish Cancer Registry (Storm
et al, 1997), the population-based Danish Hospital Discharge
Registry (Andersen et al, 1999) and a clinical database (Gjerris
et al, 1998), established by a collaboration between the major
neurosurgical, pathological, paediatric and radiological hospital
departments in Denmark and updated through the 1990s. We used
wider criteria than those of Birch and Marsden (1987), when we
identified potential CNS tumours from the Danish Hospital
Discharge Registry and the clinical database, which minimised
the risk for overlooking relevant tumours. We identified 780
potentially relevant tumours and extracted all relevant data by
scrutinising their medical records. Eight potential tumours were
excluded because no or insufficient medical data could be
identified and retrieved.
We examined the medical records for the morphology and
topography of the tumour, the date of onset of symptoms, the date
of diagnosis and the conclusion drawn from preoperative
diagnostic procedures, the date of diagnosis and the presence of
hereditary syndromes that are linked to an increased risk for CNS
tumours. If the conclusion of the preoperative diagnostic
procedures clearly stated that a CNS tumour had been found
and this diagnosis was not subsequently disproved, then the
tumour was categorised as having been ‘verified’. The first
technique used to verify a tumour was defined as the verifying
diagnostic technique for that tumour. The date of diagnosis was
defined as the date of the first diagnostic procedure that raised a
suspicion of or verified a tumour. If a tumour was first discovered
at autopsy (n¼4), then the date of death was registered as the date
of diagnosis. On the basis of the medical records, each tumour was
allocated morphology and topography codes according to the
coding system of the International Classification of Diseases for
Oncology (ICD-O) (World Health Organisation (WHO), 1976).
Of the 772 potential tumours for which medical records were
available, 146 were excluded because the morphology did not
qualify as a CNS tumour (e.g. hamartomas and arachnoid cysts)
(n¼100) or because the date of diagnosis was after the 15th
birthday of the patient (n¼46). Thus, 626 children with a CNS
tumour were included, of whom 514 had a histologically confirmed
specified tumour, 12 had a histologically confirmed but not
otherwise specified tumour and 100 had no microscopic con-
firmation of the tumour, which had been diagnosed only on the
basis of diagnostic imaging and clinical symptoms. We received
information about the vital status of the 626 children on 31 May
2005 from the Central Population Registry; if they were dead or
had emigrated or disappeared, the date of that event was recorded.
In addition, we could, up to 31 December 2001, obtain detailed
data on the cause of death in the nationwide Danish Mortality
Registry (Juel and Helweg-Larsen, 1999), where we identified 278
children who had died during 1980–2001 with a CNS tumour as
the underlying cause of death.
Statistical methods
From the Danish Statistics Bureau, we determined the size of the
Danish childhood population by age and gender for each year, and
used the data to calculate incidence rates year-by-year and
standardised for age in the age groups 0, 1–4, 5–9 and 10–14
years according to the age distribution of the Danish childhood
population in 1988, which is the mid-year of the study period. The
graphical representation of the results was based on these yearly
rates, with a smoothing spline to indicate temporal patterns. The
graphical presentation indicated that the incidence rate jumped to
a higher level from 1987 to 1988. Therefore, we fitted both a jump
model and a linear model to the incidence data. The jump model
allowed a constant annual increase (or decrease) from 1980 to
1987, a new level in 1988 and a constant annual increase (or
decrease) from 1988 to 1996. We tested if the jump model fitted
better to the incidence data than a linear model by use of the
likelihood ratio test; both models included variables for sex and
four age groups. We further explored the temporal trends in
annual incidence and mortality rates by Poisson regression
analyses, in which we modelled the effect of calendar time as a
linear trend and adjusted for age in the four age intervals.
Temporal trends were estimated as the annual change in
percentage, with confidence intervals (CI) based on Wald test;
likelihood ratio tests were used to test for statistical significance.
All statistical tests were two-sided. We used SAS PROC GENMOD
(version 8.2) for the estimations.
We used time between onset of symptoms and date of diagnosis
as a general indicator of diagnostic efficiency. The temporal trend
was analysed by standard linear regression analysis (PROC GLM,
SAS version 8.2), with time between onset of symptoms and
diagnosis as the dependent variable and year of diagnosis as the
independent variable. The distribution of time between onset of
symptoms and diagnosis was right-skewed in this material and was
therefore transformed by the natural logarithm. In these analyses,
we excluded 23 children for whom the date of onset of symptoms
was not registered in their medical records. Temporal trends in age
at diagnosis were analysed by standard linear regression with age
at diagnosis as the dependent variable and year of diagnosis as the
independent variable. We investigated the survival of children who
received their diagnosis during the first (1980–1987) and last
(1988–1996) part of the study period by Kaplan–Meier plots.
Differences in survival were tested by a Cox proportional hazard
model (PROC PHREG, SAS version 8.2), with adjustment for sex,
age (0, 1–4, 5–9 and 10–14 years), morphological type (pilocytic
astrocytoma, other astrocytoma, primitive neuroectodermal tu-
mour, ependymoma, other glioma, other) and location in the CNS
(cerebellum, cerebrum, brain stem, other). Four CNS tumours first
verified at autopsy were included in the survival analyses with an
observation time equal to zero.
In a post hoc analysis, we used the most recent data from the
Danish Cancer Registry to explore childhood CNS tumour
incidence rates (age standardised to the 1988 population) for the
5 years (1997–2001) following the study period. Medical records
were not available for these patients.
RESULTS
CNS tumours in children
Of the 626 incident childhood CNS tumours diagnosed between
1980 and 1996, 29% was located in the cerebellum, 28% in the
cerebrum, 13% in the brain stem and 30% in other locations
(Table 1); 84% had been histologically verified. Overall, the
incidence rate was 39.5 per million population-years, with slightly
higher rates among younger children (0–4 years) than among
older children (5–14 years). In younger children, the incidence
rate was 7% higher among girls than among boys, whereas among
older children the incidence rate was 22% higher among boys than
among girls. Twenty-five children had Recklinghausen neuro-
fibromatosis and four children had tuberous sclerosis. With regard
to tumour type, 39% of the patients had astrocytomas, 18% had
primitive neuroectodermal tumours, 9% had ependymomas, 3%
had other gliomas and 31% had other tumours, including tumours
of unspecified histological type.
Time trends in incidence rates
The yearly incidence rate of childhood CNS tumours increased
from about 30 to about 50 per million population during the 17-
year study period (Figure 1). A jump model did not fit better to the
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whole study period (P¼0.55). In a linear model, the incidence rate
for all CNS tumours increased by 2.9% per year (95% CI: 1.3; 4.5)
(Table 2). The incidence rate increased consistently for all
morphological subgroups, except for the small subgroup of ‘other
gliomas’. The most pronounced increase over the study period was
seen for astrocytomas and primitive neuroectodermal tumours. In
particular, the incidence of the subgroup of pilocytic astrocytomas
increased by almost 12% per year during the study period, whereas
those of the other subgroups increased by 1–3% per year. The
incidence rates of tumours of all four sites in the CNS increased,
but most markedly for tumours of the cerebrum and of ‘other’
locations in the CNS (Table 2).
The incidence rate increased by 3.9% (95% CI: 1.7;6.2 %) per
year for boys and by 1.7% (95% CI:  0.6;4.1%) for girls, but the
proportion of cases in boys during the first half of the study period
did not differ significantly from that in the last half (51% of 264
cases vs 56% of 362 cases, P¼0.25).
The incidence rate increased by 3.7% (95% CI: 0.9;6.5%) per
year for children aged 0–4 years and by 2.4% (95% CI: 0.5;4.5 %)
per year for children aged 5–14 years. Hence, the proportion of
cases in 0–4 year-old children increased from 30% during 1980–
1987 to 38% during 1988–1996 (P¼0.03), and the mean age at
diagnosis fell from 7.6 years in the first half of the study period
(1980–1987) to 6.9 years in the last half (1988–1996). The annual
decrease in the mean age throughout the period was estimated to
be 0.11 year (95% CI:  0.20;–0.02 year) per calendar year.
The proportion of CNS tumours in children with a hereditary
syndrome was 4% (n¼10) in the first half of the study period and
5% (n¼19) in the last half.
A post hoc analysis based only on data from the Danish Cancer
Registry showed that the age-standardised incidence rates for
childhood CNS tumours were 49.4, 42.9, 48.7, 39.8 and 45.4 for the
5 years following the present study (1997–2001).
Diagnostic procedures
According to information provided by Danish hospitals, the first
CT scanners were introduced in the largest hospitals during the
mid-1970s, and CT scanners gradually became available at the
Table 1 Numbers and crude rates (per million population-years) of incident CNS tumours in Denmark, 1980–1996, by age, gender, tumour morphology
and location in the brain
Age 0–14 years Age 0–4 years Age 5–14 years
Both sexes Boys Girls Both sexes Boys Girls Both sexes Boys Girls
Tumour definition n Rate n Rate n Rate n Rate n Rate n Rate n Rate n Rate n Rate
All CNS tumours 626 39.5 337 41.5 289 37.3 216 42.8 107 41.4 109 44.2 410 37.9 230 41.6 180 34.1
Tumour morphology
Astrocytomas 247 15.6 123 15.2 124 16.0 83 16.4 39 15.1 44 17.9 164 15.2 84 15.2 80 15.1
Primitive neuroectodermal tumours 111 7.0 64 7.9 47 6.1 42 8.3 19 7.3 23 9.3 69 6.4 45 8.1 24 4.5
Ependymomas 58 3.7 31 3.8 27 3.5 33 6.5 16 6.2 17 6.9 25 2.3 15 2.7 10 1.9
Other gliomas 20 1.3 9 1.1 11 1.4 3 0.6 0 0 3 1.2 17 1.6 9 1.6 8 1.5
Others
a 190 12.0 110 13.6 80 10.3 55 10.9 33 12.8 22 8.9 135 12.5 77 13.9 58 11.0
Tumour topography
Cerebellum 183 11.5 100 12.3 83 10.7 64 12.7 30 11.6 34 13.8 119 11.0 70 12.7 49 9.3
Cerebrum 175 11.0 97 12.0 78 10.1 62 12.3 35 13.5 27 11.0 113 10.5 62 11.2 51 9.7
Brain stem 79 5.0 44 5.4 35 4.5 21 4.2 10 3.9 11 4.5 58 5.4 34 6.2 24 4.5
Other locations 189 11.9 96 11.8 93 12.0 69 13.7 32 12.4 37 15.0 120 11.1 64 11.6 56 10.6
CNS, central nervous system.
aIncluding those without histological confirmation.
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Figure 1 Annual incidence rates (per million) of CNS tumours among
Danish children, 1980–1996, age standardised to the Danish childhood
population in 1988. A smoothing spline indicates the temporal pattern.
Table 2 Annual changes in CNS tumour incidence rates in Danish
children, 1980–1996
Tumour definition n
Percent change in
incidence rate per
year (95% CI) P-value
All CNS tumours 626 2.9 (1.3;4.5) 0.0005
Tumour morphology
Astrocytoma 247 4.4 (1.8;7.0) 0.0009
Pilocytic
astrocytomas
66 11.9 (6.2;17.9) o 0.0001
Other
astrocytomas
a
181 1.9 (– 1.0;4.9) 0.21
Primitive
neuroectodermal
tumours
111 2.9 (–0.9;6.8) 0.13
Ependymoma 58 1.8 (–3.3;6.9) 0.49
Other glioma 20 –0.7 (–9.2;8.5) 0.87
Others 190 1.6 (–1.3;4.6) 0.27
Not histologically
verified
100 1.0 (–2.9;5.1) 0.61
Tumour topography
Cerebellum 183 1.3 (–1.6;4.2) 0.40
Cerebrum 175 4.6 ( 1.5;7.8) 0.003
Brain stem 79 2.1 (–2.3;6.7) 0.35
Other locations 189 3.2 (0.3;6.2) 0.03
CI, confidence interval; CNS, central nervous system.
aIncluding astrocytomas, not
otherwise specified.
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was introduced in Denmark in 1984 and the next four in 1989; the
MRI capacity then gradually increased during the 1990s. Examina-
tion of the medical records showed that MRI was used to verify a
childhood CNS tumour for the first time in Denmark in 1985, and
the proportion of CNS tumours verified in this way increased
slowly throughout the study period. Computed tomography
remained the procedure of choice for verifying the majority of
CNS tumours throughout the study period (Figure 2). Tumours
classified as ‘others’, including ‘not histologically verified’,
represented the largest proportion of tumours verified by MRI,
whereas pilocytic astrocytoma and primitive neuroectodermal
tumours represented the smallest proportions. Tumours of the
brain stem and ‘other location’ were most frequently verified by
MRI, whereas tumours of the cerebellum were most rarely verified
in this way (Table 3).
The number of days between the onset of symptoms and
diagnosis decreased during the study period, with a mean of 360
days in the period 1980–1987 (maximum: 12.7 years) and 257 days
in the period 1988–1996 (maximum: 12.8 years), for an estimated
2.7% decrease per year (95% CI: 0.3;5.2%) for the entire study
period (Table 4). The annual decrease was 5% for nonpilocytic
astrocytomas and ependymomas, whereas there was virtually no
change over time for pilocytic astrocytomas. Tumours of the
cerebrum were associated with the most pronounced decrease in
time between the onset of symptoms and diagnosis.
CNS tumour-specific mortality rates
The results indicated an increase in the CNS tumour-specific
mortality rate for children between 1980 and 2001. In a linear
model, the annual increase was 1.4% (95% CI:  0.4;3.3%; P¼0.12;
n¼278). The increase was slightly higher for children aged 0–4
years, among whom the mortality rate increased by 1.8% per year
(95% CI:  1.3;5.0%; P¼0.26; n¼99) than for children aged 5–14
years with an estimated annual increase of 1.3% (95% CI:
 1.0;3.6% increase; P¼0.28; n¼179).
Survival
Survival after a diagnosis of a CNS tumour was almost constant for
children aged 0–4 years throughout the study (P¼0.99), whereas
the survival of children aged 5–14 years improved significantly
between the first and the last parts of the study (Po0.0001)
(Figure 3), such that the 10-year survival increased from 59 to 74%.
DISCUSSION
This study shows that the incidence rate of CNS tumours among
Danish children increased significantly between 1980 and 1996,
both for the young (0–4 years) and the older children, with
increases for all major morphological and topographical sub-
groups. Overall, these findings agree with those of most previous
studies (Blair and Birch, 1994; McKinney et al, 1994; Bunin et al,
1996; Gurney et al, 1996; Hjalmars et al, 1999; McNally et al, 2001;
Dreifaldt et al, 2004), although differences have been found. Thus,
a British study showed a stable rate of ependymomas (McNally
et al, 2001), one study in the USA showed a stable rate of primitive
neuroectodermal tumours (Gurney et al, 1996) and another study
in the USA, spanning 21 years, showed that increases in the
incidence rates of various morphological subgroups depends on
the period studied (Linet et al, 1999). Several aspects of and
possible explanations for the increase in incidence rates and
methodological aspects of the present study must be considered.
First, the number of CNS tumours analysed in the present study
(n¼626) limited the statistical power for some of the subgroup
analyses and precluded analyses of combinations of morphological
and topographical subgroups, as was carried out in a larger data
set (Smith et al, 1998). However, the limited number of tumours
facilitated the detailed registration of diagnostic method, time of
onset of symptoms and time of diagnosis for each child, which
gave us a unique and precise picture of the temporal pattern of use
and efficiency of diagnostic methods and the true mortality and
survival rates in the present population-based study.
Second, changes in the reliability of tumour registration and
disease classification can influence registered incidence rates of
CNS tumours. Cases were identified from a nationwide, clinical
CNS tumour database and two independent population-based
registers, both of which benefit from mandatory registration,
resulting in virtually complete case ascertainment. In addition, use
of medical records, including reports on pathology and neuroima-
ging, ensured better validity of the diagnoses than cancer registry
data alone (McKinney et al, 1994; Thorsteinsson et al, 2005).
Furthermore, the same persons coded all the tumours according to
the ICD-O to ensure consistent coding practice. The registration
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Figure 2 Percentage of childhood CNS tumours diagnosed in Denmark,
1980–1996, for which CT scanning (dots) or MR scanning (triangles),
respectively, was the first method used to verify the tumour. Ten tumours
were excluded as they had been verified by both CT and MRI on the same
day.
Table 3 Methods for verification of 454 childhood CNS tumours in
Denmark in the period 1985–1996
CT MRI Others
a
Tumour definition % n % n % n
All CNS tumours 78 355 14 62 8 37
Tumour morphology
Astrocytoma 79 147 13 24 8 14
Pilocytic astrocytoma 89 47 6 3 6 3
Other astrocytomas
b 76 100 16 21 8 11
Primitive neuroectodermal tumours 89 73 5 4 6 5
Ependymoma 77 30 13 5 10 4
Other glioma 57 8 14 2 29 4
Others 72 97 20 27 7 10
Not histologically verified 71 50 26 18 3 2
Tumour topography
Cerebellum 89 116 5 6 6 8
Cerebrum 77 103 12 16 11 15
Brain stem 71 40 23 13 5 3
Other locations 72 96 20 27 8 11
CT, computed tomography; CNS, central nervous system; MRI, magnetic resonance
imaging.
aIncluding histological investigation (n¼11), autopsy (n¼3), myelography
(n¼3) and ultrasound (n¼1), more than one method verified the tumour on the
same day (n¼13) and unknown owing to missing results from the first scanning in
the medical records (n¼6).
bIncluding astrocytomas, not otherwise specified.
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voluntary notification of incident cancer cases from 1943, became
compulsory from 1987 (Storm, 1991). The procedures, including
registration of benign CNS tumours, were not changed, but the
change could have led to a more complete registration. However,
previous analyses of the change from voluntary to compulsory
reporting have indicated no overall effect on the number of cancers
reported (Storm et al, 1997). Furthermore, the Danish Cancer
Registry is only one of three sources used to identify the CNS
tumours in the present study, and the two other sources would not
be affected by the change to compulsory notification to the Danish
Cancer Registry. Finally, 1987 was the first year where the Danish
Cancer Registry used the Danish Hospital Discharge Registry as an
additional source to identify incident cancer cases, which led to a
slight increase in the completeness of the Cancer Registry from
1987 (Storm et al, 1991). However, in the present study, we also
identified potential childhood CNS tumours in the Danish Hospital
Discharge Registry for the years 1980 to 1986 to ensure consistent
data sources for the present study over the whole study period
from 1980 to 1996.
Third, the greater increase in the incidence rate of slowly
growing, benign tumours than of more aggressive tumours might
indicate that heightened awareness of such tumours, improved
diagnostic methods or improved access to diagnosis could explain
the increase in childhood CNS tumour incidence, as these slowly
growing tumours might otherwise have remained undetected,
perhaps throughout life (Gurney et al, 1996; Smith et al, 1998).
Accordingly, one Swedish study (Dreifaldt et al, 2004) also found a
greater increase in the incidence rate of benign CNS tumours than
of other types of CNS tumours, whereas another Swedish study
(Hjalmars et al, 1999) found that the incidence rate increased to a
greater extent for grade 3–4 than for grade 1–2 astrocytomas. We
found the most pronounced increase in the annual incidence rate
of slowly growing pilocytic astrocytomas, which have a good
prognosis (Gjerris et al, 1998; Fernandez et al, 2003); however, the
time between the onset of symptoms and diagnosis of pilocytic
astrocytoma remained stable throughout the study, suggesting that
earlier detection played only a minor role, if any. Furthermore, the
second highest increase in annual incidence rate was for aggressive
primitive neuroectodermal tumours, which have a poor prognosis
(Lannering et al, 1990; Gjerris et al, 1998; Alston et al, 2003;
Viscomi et al, 2003), with only a modest decrease in time between
the onset of symptoms and diagnosis during the study period.
Finally, the incidences of tumours in all the major morphological
subgroups increased, as did that of tumours that were not
histologically verified, although they continued to constitute a
minor proportion of CNS tumours. We cannot rule out the
possibility that changes in tumour classification and new
histomorphological analyses could have influenced the incidence
rates of specific histological subgroups over time, but this would
not explain the general pattern of increasing incidence rates in the
present study. Moreover, histopathological re-evaluation and
homogeneous morphological classification of all CNS tumours in
a British series excluded temporal changes in classification
practices as a plausible explanation for the observed increase in
the incidence rate (McNally et al, 2001).
Fourth, improved access to MRI could change the registered
incidence even if the biological incidence is unchanged. Thus, the
introduction and use of MRI have been suggested as a possible
explanation for registered increases in the incidence rate for
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Figure 3 Kaplan–Meier plots of survival after a diagnosis of a CNS
tumour in Denmark in 1980–1987 and 1988–1996. The upper panel
shows children aged 0–4 years, and the lower panel represents children
aged 5–14 years at the time of diagnosis.
Table 4 Percentage annual change in time from the onset of symptoms to diagnosis for 603 childhood CNS tumours in Denmark, 1980–1996
Tumour definition n % change per year 95% CI P-value
All CNS tumours 603  2.7  5.2; 0.3 0.03
Tumour morphology
Astrocytoma 241  3.6  7.3;0.1 0.06
Pilocytic astrocytoma 64  0.3 –8.1;8.2 0.95
Other astrocytomas
a 177  4.6  8.7; 0.2 0.04
Primitive neuroectodermal tumours 108  1.8  6.2;2.9 0.45
Ependymoma 53  4.8  10.5;1.3 0.13
Other glioma 18  18.6  31.8; 2.9 0.04
Others 183 1.1  4.0;6.5 0.69
Not histologically verified 96  1.7  8.7;5.7 0.64
Tumour topography
Cerebellum 176  1.9  5.8;2.1 0.34
Cerebrum 170  7.1  11.7; 2.3 0.005
Brain stem 78  1.8  8.0;4.8 0.59
Other locations 179  0.4  5.0;4.4 0.86
CI, confidence interval; CNS, central nervous system.
aIncluding astrocytomas, not otherwise specified.
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during the few year where MRI was introduced (Black, 1998; Smith
et al, 1998). This explanation is not, however, supported by the
detailed data presented in our study. A jump model did not fit the
incidence data better than a linear model and the proportion of
CNS tumours verified by MRI remained relatively low throughout
the study period. Thus, fluctuations in the annual incidence rates,
for example, from 1987 to 1988, could well represent stochastic
variation. Furthermore, the morphological tumour types (pilocytic
astrocytomas and primitive neuroectodermal tumours) for which
the incidence rates increased most markedly were rarely initially
verified by MRI. This fact does not exclude the possibility that
wider access to MRI and improvements in CT scanners during the
1980s and 1990s might have increased the diagnosis of a few small
tumours that would otherwise have remained undetected. The
overall increase in both CT and MRI capacity in Denmark during
the study period expanded their use for patients with focal epilepsy
and nonspecific CNS symptoms, including endocrine disturbances
and behavioural changes, although no data are available to
quantify this effect.
Fifth, easier access to CT and MRI scans would be expected to
shorten the interval between emergence of symptoms and
diagnosis and to reduce the age at diagnosis. The incidence would
be increased in the youngest age group because age at diagnosis
cannot be displaced further downwards for this group. In
agreement with this hypothesis, some (Bunin et al, 1996; Gurney
et al, 1996) but not all (Smith et al, 1998) previous studies as well
as ours indicate a more pronounced increase in the incidence rate
among children aged 0–4 years than among those aged 5–14
years. As the incidence also increased in the older age groups,
however, this explanation is insufficient for the present results.
Sixth, and most important, if readier access to CT or MRI scans
led to a registered but not a biologically based increase in the
incidence of childhood CNS tumours, one would expect an
improved survival and an unchanged or even reduced specific
mortality rate. Most previous studies (Mosso et al, 1992; Linet
et al, 1999; Kaatsch et al, 2001; Gonzalez et al, 2004), but not all
(Shugg et al, 1994) have found decreases in mortality from CNS
tumours in childhood over the past three decades, probably owing
to improved therapy. In the present study, however, we observed
an annual 1.4% increase in mortality rate (younger children 1.8%;
older children 1.3%), which indeed supports that the observed
annual 2.9% increase in incidence rate (younger children: 3.7%;
older children: 2.4%) is biologically true. On the other hand, the
observed increased survival after a CNS tumour among 5–14-year-
old children is compatible with both improved therapy and
improved diagnostic methods leading to the detection of tumours
that would not previously have been detected before the 15th
birthday, but none of these explanations could explain the
observed increase in the mortality rate.
In summary, the results of the present study suggest that the
incidence rate of CNS tumours among Danish children has truly
increased, although additional aspects of the increasing incidence
rate must be considered.
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